Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
Status:
Terminated
Trial end date:
2017-04-24
Target enrollment:
Participant gender:
Summary
Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK),
and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination
with intravenous (IV) docetaxel in subjects with advanced solid tumors.